Navigation Links
Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint

with Hepsera for a median of 49 weeks up to a maximum of 240 weeks. Changes in serum creatinine were observed very commonly in patients pre- and post-transplantation with lamivudine-resistant liver disease and multiple risk factors for changes in renal function who were treated with Hepsera for up to 129 weeks, with a median time on treatment of 19 and 56 weeks, respectively. Clinical and laboratory evidence of exacerbations of hepatitis have occurred after discontinuation of treatment with antiviral therapies for hepatitis B, including Hepsera. Special warnings and precautions for use are included in the package insert regarding monitoring of renal function, post-treatment exacerbations of hepatitis, and the occurrence of lactic acidosis and severe hepatomegaly with steatosis. Dosing instructions for patients with underlying renal impairment and for patients co-infected with HIV are also provided in the package insert, which is available for download online at www.hepsera.com.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia. For more information on Gilead Sciences, please visit the company's website at www.gilead.com or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including risks related to Gilead's ability to successfully commercialize tenofovir DF for chronic hepatitis B. For example, the FDA may not approve tenofovir DF for the treatment of chronic hepatitis B in the United States, and marketing approval, i
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/19/2014)...  BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a ... XIAFLEX ® in the U.S. and XIAPEX ® ... Wegman , will present a corporate overview at the 21 ... The presentation will take place on Friday, ... Broadway Hotel in New York, NY . ...
(Date:9/19/2014)... September 19, 2014 Aufgrund ... den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch ... PDF, verfügbar unter pharmaserialisation.com , zeigt die ... jeweils in Kraft treten. Für international ... länger um das "ob", sondern darum, "wann" sie ...
(Date:9/19/2014)... VIENNA , Sept. 19, 2014 ... positive interim clinical data for its lead candidate ITCA ... diabetes patients with high baseline HbA1c levels at the ... for the Study of Diabetes (EASD). Data from the ... reduced levels of blood sugar in patients with poorly ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... and Staff Will Focus on Advances in ... and Treatment of Lung Cancer in Women, SEATTLE, Sept. ... the Society for Women,s Health,Research, the Lung Cancer Alliance and ... Matters to Research," on,Capitol Hill to discuss advances in the ...
... Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced today that ... clinical development and discovery,programs at four upcoming investor conferences: ... Presentation: Monday, September 17, 2007 at 10:00 a.m. Pacific ... the St. Regis Hotel in San Francisco ...
Cached Medicine Technology:Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill 2Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill 3Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences 2Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences 3
(Date:9/19/2014)... M.D., a second-year resident in the Department of ... Medicine and Health Sciences, received at $154K grant ... presence of diffuse brain swelling and injury in ... epidemiological studies, intracerebral hemorrhage accounts for less than ... least treatable form of stroke, with the highest ...
(Date:9/19/2014)... September 19, 2014 Top 10 ... recently announced that HostGator.com, GoDaddy and Bluehost are ... These companies are the most recommended suppliers for ... Europe to buy high quality Linux hosting (including ... ) is one of many top hosting companies ...
(Date:9/19/2014)... Capital Region Periodontics and Dental Implants, led ... the latest addition to their treatment options for ... dental implants. Often referred to as the “gentle ... factor normally associated with traditional gum surgery. No ... this procedure a very attractive oral surgery alternative ...
(Date:9/19/2014)... receive any palliative care, reveals new research to be ... in Madrid, Spain, 26-30 September. The findings are astonishing ... new oncology centres in Europe, Canada, South America and ... Designated Centre of Integrated Oncology and Palliative Care., , ... the Institute of Oncology Bucharest, Romania, member of the ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Follow ... part of the medical imaging market, are engineered to ... developments over the past three decades have expanded the ... barium and iodine based agents used for over half ... and radiopharmaceuticals, imaging agents have witnessed sea changes, revolutionizing ...
Breaking Medicine News(10 mins):Health News:GW researcher receives grant to study brain swelling following bleeding in the brain 2Health News:Top10BestSEOHosting.com Announces Great Linux Web Hosting Suppliers In 2014 2Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 2Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 3Health News:Patients with advanced, incurable cancer denied palliative care 2Health News:Patients with advanced, incurable cancer denied palliative care 3Health News:Patients with advanced, incurable cancer denied palliative care 4Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 2Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 3Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 4
... Calif., Jan. 15 Alpine Biomed,Corporation, a global ... has acquired Stellate Systems Inc. Headquartered in ... of advanced,neurodiagnostic systems. The acquisition is the ... Healthcare Partners, a leading private equity,firm focused exclusively ...
... action ,precautionary, as salmonella outbreak probe continues; 5 deaths ... states , , THURSDAY, Jan. 15 (HealthDay News) -- Cereal ... popular Keebler and Austin brand peanut butter crackers, ... nationwide salmonella outbreak that is linked to peanut butter. ...
... Motivation with a Value-Filled Option for Customers to Become ... help motivated consumers quit smoking and to further its ... prescription medications, Walmart today announced that it has expanded ... prescription starter pack for $9, the lowest price on ...
... Cancer patients in Estonia ... intensity modulated radiotherapy (IMRT), for the first time with ... Varian Medical Systems treatment machine at the North ... opening ceremony attracted publicity on Estonian national TV and ...
... (azelastine hydrochloride) Nasal Spray Hits U.S. Pharmacies SOMERSET, ... new medication is available to manage the symptoms ... as many as 40 million people in the ... in a unique vehicle formulated for enhanced patient ...
... to Portable Medical RecordsSCOTTSDALE, Ariz. and FAIRFAX, Va., ... Data Systems Analysts (DSA) are pleased to announce ... customers with even higher levels of security and ... Memory,s flagship product is a physician-designed system to ...
Cached Medicine News:Health News:Alpine Biomed Acquires Stellate to Create New Leader in Neurology Diagnostics Market 2Health News:Alpine Biomed Acquires Stellate to Create New Leader in Neurology Diagnostics Market 3Health News:Kellogg Halts Sales of Peanut Butter Crackers 2Health News:Kellogg Halts Sales of Peanut Butter Crackers 3Health News:Walmart Offers $9 Smoking Cessation Starter Pack 2Health News:Walmart Offers $9 Smoking Cessation Starter Pack 3Health News:Estonian Cancer Patients Have Access to More Conformal Radiotherapy Treatments for First Time with Unveiling of Advanced Varian Treatment Machine 2Health News:Estonian Cancer Patients Have Access to More Conformal Radiotherapy Treatments for First Time with Unveiling of Advanced Varian Treatment Machine 3Health News:Allergy Sufferers to Benefit from New, Improved Rapid Relief Medication This Spring 2Health News:Allergy Sufferers to Benefit from New, Improved Rapid Relief Medication This Spring 3Health News:Allergy Sufferers to Benefit from New, Improved Rapid Relief Medication This Spring 4Health News:My Medical Memory and Data Systems Analysts Partner to Provide Secure, Portable Health Records 2Health News:My Medical Memory and Data Systems Analysts Partner to Provide Secure, Portable Health Records 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: